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Abstract
Background: Portal vein stenosis develops due to different causes including postoperative inflammation and
oncological processes. However, limited effective therapy is available for portal vein stenosis. The objectives of this
study were to evaluate the efficacy of a portal vein stent for portal vein stenosis after hepatobiliary pancreatic
surgery and to determine the factors associated with stent patency.
Methods: From December 2003 to December 2015, portal vein stents were implanted in 29 patients who had
portal vein stenosis after hepatobiliary pancreatic surgery. We conducted a retrospective analysis to evaluate the
efficacy and safety of portal vein stent placement. Twelve clinical variables were analyzed for their role in stent
patency.
Results: The symptoms before portal vein stent placements included nine patients with hepatic encephalopathy,
six patients with gastrointestinal bleeding, four patients with ascites, and four patients with hyperbilirubinemia.
Portal vein thrombosis due to postoperative portal stenosis was found in four patients. Portal vein stent were
successfully implanted without any major complications. Of the 21 patients with symptoms, 17 showed improvement,
and stent patency was maintained in 22 (76%) patients. The presence of a collateral vein is the only variable related to
the development of an occlusion after portal stenting.
Conclusion: Portal vein stent were implanted safely and had good long-term patency. This procedure is useful to
relieve portal hypertension-related symptoms and to improve the quality of life. Our data strongly suggest that
embolization to block blood flow in a collateral vein during portal vein stent placement will improve the patency of
the stent.
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Background
Portal vein stenosis develops due to various causes, in-
cluding both postoperative inflammation and onco-
logical processes. Benign portal vein stenosis is a
complication associated with portal vein reconstruction
for liver transplantation and after hepatobiliary pancreatic
surgery. It is also caused by inflammation surrounding the
portal vein, such as pancreatitis [1–3]. In addition, the
incidence of portal vein stenosis due to hepatobiliary
pancreatic malignancies, including hepatocellular car-
cinoma, pancreatic cancer, and biliary tract cancer, is
15 to 24% of the cases of extraheptic portal vein sten-
osis [4–6]. Furthermore, portal vein stenosis is likely to
develop due to local recurrence after hepatobiliary pan-
creatic surgery [7, 8]. Portal vein stenosis is associated
with portal hypertension and with the development of
varices in the esophagus, stomach, duodenum, and
small bowel. These varices frequently cause refractory
gastrointestinal (GI) bleeding [9, 10]. Portal hypertension
is also a cause of liver dysfunction associated with both ab-
dominal ascites and hepatic encephalopathy.
* Correspondence: a-kato@umin.ac.jp
Department of General Surgery, Chiba University Graduate School of
Medicine, 1-8-1 Inohana, Chuo-ku, Chiba 260-8670, Japan
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kato et al. BMC Surgery  (2017) 17:11 
DOI 10.1186/s12893-017-0209-y
Limited effective therapy is available for portal vein
stenosis. A recent study of the clinical efficacy of portal
vein stent placement in patients with either malignant
tumors or benign portal stenosis showed that portal
hypertension was improved, and clinical symptoms were
resolved [11, 12]. On the other hand, thrombus and/or
tumor growth sometimes cause re-occlusion, and the
stent patency rate is 60–100% [13–15].
The objectives of this study were to evaluate the effi-
cacy of portal vein stent placement for portal vein sten-
osis after hepatobiliary pancreatic surgery and to identify
the factors involved in stent patency.
Methods
Patients
From December 2003 to December 2015, portal vein
stents were implanted at a single institution in 29 patients
(21 males and 8 females, mean age 65.9 ± 10.0 years, range
38–83 years) who had portal vein stenosis after hepatobili-
ary pancreatic surgery. We retrospectively reviewed the
clinical data of these 29 patients.
Postoperative pathological diagnosis showed intrahe-
patic cholangiocarcinoma in three patients, extrahepatic
cholangiocarcinoma in 13, gallbladder cancer in 1, pan-
creatic cancer in 8, intraductal papillary mucinous neo-
plasms in 2, autoimmune hepatitis in 1, and Budd-Chiari
syndrome in 1. In terms of surgical procedures, liver re-
section was performed in 15 patients (live donor liver
transplant in two patients), and pancreatic resection was
performed in 14 patients. Portal vein resection and re-
construction were performed in 14 patients. The clinical
characteristics of these patients are shown in Table 1.
Ten patients with vascular-orientated benign stenosis
developed portal vein stenosis, and the remaining 19 pa-
tients had portal vein stenosis due to tumor recurrence.
All of the patients were diagnosed with portal vein sten-
osis by enhanced CT. Portal vein stenosis was localized
in the region extending from the superior mesenteric
vein (SMV) to the portal vein (PV) in 13 patients, and
the main portal vein was stenosed in 16 patients. Four
patients, who had developed stenosis early after surgery
due to portal vein thrombosis, underwent surgical
thrombectomy and stenting in the portal vein via the
ileocolic vein during surgery. In three patients, who had
developed portal vein stenosis after surgery, we tried
to reconstruct the portal vein. However, we could not
detach the severe adhesion to the portal vein and per-
formed portal vein stent placement via the ileocolic
vein during surgery.
Symptoms
The major symptom found in nine patients was hepatic
encephalopathy. GI bleeding was found in six patients,
ascites was found in four patients, and hyperbilirubinemia
was found in two patients. Portal vein thrombosis due to
postoperative portal stenosis was found in four patients.
The remaining four patients had no symptoms. These
asymptomatic patients were as follows: one patient who
underwent a live donor liver transplant had marked
stenosis in the anastomotic site of the portal vein and
underwent portal vein stent placement to prevent portal
vein occlusion. Three patients receive a portal vein stent,
including one patient with portal vein stenosis due to
postoperative inflammation and two patients with portal
vein stenosis caused by a recurrent tumor.
Stent placement
Informed consent was obtained from all of the patients
and their families prior to portal vein stent placement.
The portal vein stents were implanted by two procedures.
The procedures included ultrasonography (US)-guided
percutaneous transhepatic puncture of the intrahepatic
portal vein and a surgical approach for insertion via the
Table 1 Characteristics of patients (n = 29) with portal vein
stent placement
Age (mean year ± SD) 65.9 ± 10.0
Sex (mail: female) 21: 8
Pathological Diagnosis
Biliary Tract Cancer 17
Pancreas Cancer 8
Intraductal Mucinous Papillary Neoplasms 2
Autoimmune Pancreatitis 1









Superior Mesenteric Vein - Portal Vein 13







Anticoagulation (days) 1.75 ± 2.34
PV pressure (mm H2O) 35.2 ± 6.2
Stent Patency (days) 519 ± 643
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ileocolic vein. A 5-French sheath was inserted into the
portal vein, and portography using a catheter was per-
formed in both procedures. After that, the length of the
stenotic segment was determined, and a self-expandable
metallic stent was placed in the stenotic region. When
selecting a stent, it is ideal to choose a stent that is ap-
proximately 1 cm longer at both ends of the collapse. A
collateral vein was found in 17 patients. However, the
blood flow in the collateral vein immediately disappeared
after stenting, and no embolization of the collateral vein
was performed. Patients who had portal vein stenosis after
stenting the portal vein due to insufficient expansion of
the stent underwent balloon dilation in the stenotic area.
Anticoagulation therapy with heparin sodium was used
for all patients within 0–7 days after portal vein stent
placement. Subsequently, warfarin potassium, an oral
anticoagulant, was administered to maintain the inter-
national normalized ratio of prothrombin time (PT-INR)
at 1.5–2.0 for at least 1 year.
Follow-up
Complications with the stent placement were evaluated.
Stent patency was evaluated at intervals of 2–3 months
for the first year and at intervals of 3–6 months there-
after by measuring the blood flow in the stent using ei-
ther Doppler US or contrast-enhanced CT. The blood
flow in the stent was evaluated immediately if portal
hypertension developed clinically. The patency period
was defined as the time from stent placement to stent
occlusion. The mean follow-up period for all patients
was 19.1 ± 24.9 months.
Twelve variables, including age, sex, pathological diag-
nosis, surgical procedures, portal vein combined resec-
tion, etiology, involved vessels, lesion length, presence of
a collateral vein, type of stent procedure, time of starting
anticoagulation therapy, and portal vein pressure before
stenting, were used to confirm whether these variables
were associated with stent patency.
Data analyses
Differences between the matched groups were evaluated
using the Fisher’s exact test for paired proportions for
categorical variables. The overall stent patency was cal-
culated according to the Kaplan–Meier method. Statis-
tical significance was defined by p values less than 0.05.
Results
Portal vein stent placement was successfully performed,
and blood flow in the portal vein was confirmed in all
patients. No serious complications, excluding a minor
complication (transient fever) in three patients, were ob-
served after portal vein stent placement. Furthermore,
no hemorrhagic complications due to anticoagulation
therapy after stenting were found.
Stent placement was performed by a percutaneous
transhepatic approach in 22 patients and by a laparotomy
via the transileocolic vein in seven patients. Four of the
seven patients who underwent stent placement via the
transileocolic vein had acute portal vein thrombosis, and a
stent was placed in a stenotic region after thrombectomy.
Two patients, who were found to have portal vein stenosis
after a live donor liver transplant, were unable to have re-
anastomosis of the portal vein. Therefore, stent placement
via the transileocolic vein was performed.
Stent patency was maintained in 22 (76%) of the 29
patients during the observation period, and the mean stent
patency period in all patients was 17.3 ± 21.4 months (1–
2318 days) (Fig. 1). Stent occlusion was found in seven pa-
tients, including three with acute stent occlusion due to
thrombosis, in one patient with stent occlusion due to
thrombosis at 80 days after stenting, and in three patients
with stent occlusion due to tumor growth at 145 to
1827 days after stenting. No further intervention including
thrombectomy or re-stentig was performed in patients
with portal stent occlusion because of general poor condi-
tion. Of the 21 patients with symptoms, 17 had improved
symptoms after the stent placement. Two patients, who
had hepatic encephalopathy with acute stent occlusion
due to thrombosis early after stenting, did not improve.
These two patients with acute stent occlusion were
followed up without re-stenting, and the symptoms grad-
ually resolved in one of the patients via development of a
collateral vein. For the other patient, the symptoms were
relieved by conservative therapy until the patient died due
to cancer recurrence approximately 9 months later. One
patient with ascites and one patient with hyperbilirubine-
mia did not improve after stenting.
The relationship between the 12 variables and stent
patency was evaluated (Table 2). The presence of a col-
lateral vein was the only variable associated with the
development of stent occlusion (Fig. 2). Factors related
Fig. 1 Kaplan-Meier cumulative portal vein stent patency in
29 patients
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to acute stent occlusion were evaluated but no statisti-
cally significant factor was identified.
Discussion
Postoperative portal vein stenosis is a surgical complication
seen either after anastomosis of the portal vein or inflection
of the portal vein during hepatectomy, pancreatectomy,
and liver transplantation. Consequently, portal vein occlu-
sion is frequently complicated by thrombosis. Since portal
vein stenosis is likely to occur early after surgery, it is
necessary to monitor the portal flow using color Doppler
US [16, 17]. On the other hand, patients who developed
local recurrence surrounding the portal vein after radical
resection for hepatobiliary pancreatic cancer often have
portal vein stenosis.
Many patients have portal hypertension due to both
postoperative portal vein stenosis and occlusion, and
these patients also develop refractory ascites, GI bleed-
ing, and hepatic encephalopathy associated with elevated
blood ammonia caused by the portal-systemic shunt.
Postoperative portal vein stenosis not only increases
morbidity and mortality but also has an effect on the
long-term quality of life (QOL).
Four of our patients with portal vein stenosis that de-
veloped early after surgery had complicated portal vein
thrombosis, a thrombectomy, and then a portal vein
stent placement that successfully perfused blood flow in
the portal vein. Refractory ascites associated with portal
hypertension was found in four patients, GI bleeding in
six patients, hepatic encephalopathy in nine patients,
and hyperbilirubinemia in two patients. All of these
patients underwent portal vein stent placement. The
symptoms improved in 17 of the 21 patients (81%).
Thereafter, the patients had a good QOL. Serious com-
plications after portal vein stent placement, including hep-
atic artery aneurysm and liver abscess, have been reported
with the use of the hemoperitoneum for the percutaneous
transhepatic approach and with the use of the ileus for
the transileocolic approach [11, 15]. However, the inci-
dence of serious complications in those studies was
low. In fact, no serious complications were observed
after portal vein stent placement in our study. Thus,
these procedures were performed in an extremely safe
manner with a low incidence of complications.
There are several studies on the long-term durability
of portal vein stent placement. Tsukamoto et al. showed
that the stent patency rate was 100% for the observation
period of 27.9 ± 10.7 months in seven patients with ma-
lignant portal vein stenosis [13]. Ko et al. reported that
the stent patency rate was 78% for the observation
period of 66.6 ± 16.1 months in nine patients with portal
vein stenosis after a live donor liver transplant [14]. Kim
et al. indicated an 89% stent patency rate for the obser-
vation period of 23.5 ± 22.5 months in 19 patients with
Table 2 Portal venous stent patency in patients (n = 29)
following postoperative portal vein stenosis
Variables Patency p value
Yes No
Age ≤69 years old 10 5
>69 years old 12 2 0.2310
Sex Male 17 4
Female 5 3 0.2993
Pathological Diagnosis Benign 2 0
Malignant 20 7 0.4084
Surgical Procedure Liver Resection 11 4
Pancreas Resection 11 3 0.7419
Portal Vein Combined Resection Yes 11 3
No 11 4 0.7419
Etiology Tumor Recurrence 14 5
Vascular Orientated 8 2 0.7056
Involved Vessels PV 13 3
SMV-PV 9 4 0.4519
Lesion Length ≤16 mm 10 5
>16 mm 12 2 0.2310
Collateral Vein Yes 10 7
No 12 0 0.0107a
Stent Procedures Transhepatic 15 7
Transileocolic 7 0 0.0866
Anticoagulation Therapy ≤1 day 17 6
>2 day 4 1 0.7757
PV pressure ≤33.5 mmH2O 10 1
>33.5 mmH2O 7 3 0.2230
PV portal vein, SMV superior mesenteric vein
aDenotes statistical significance
Fig. 2 Kaplan-Meier cumulative portal vein stent patency. The solid
line shows the cases with a collateral vein, and the dotted line
shows the cases without a collateral vein
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curative surgery for pancreatic and biliary neoplasms
[11]. Zhou et al. conducted portal vein stent placement
in patients with hepatobiliary pancreatic cancer and
showed a 75% stent patency rate for the observation
period of 13 ± 11 months [15]. We also confirmed rela-
tively good stent patency (76%) for the observation
period of 17.3 ± 21.4 months. As described above, several
studies showed relatively good stent patency for a long-
term observation period, however, there are few studies
that have analyzed the factors associated with the patency
of a portal vein stent.
Yamakado et al. showed that the stent patency rate
was 60% for the observation period of 11.9 ± 12.9 months
in 40 patients with malignant portal vein obstruction [6].
They conducted multivariate analysis and identified three
factors associated with stent occlusion, including splanchnic
vein involvement, cirrhotic patients classified as Child-Pugh
class C, and obstruction of the portal vein system. We ana-
lyzed 12 variables associated with stent patency. The pres-
ence of a collateral vein was the only variable related to the
development of stent occlusion in our study. This result
suggested that decreased blood flow in the portal vein was
related to stent occlusion. These results strongly suggested
that embolization should be performed to block blood flow
in a collateral vein in patients who develop a collateral vein.
Recently developed metallic stents are highly flexible
and expandable, and thus the length and diameter are
adjustable for placement of an appropriate sized stent
in a stenotic region. Therefore, stents can be used for
long portal vein stenosis even in the splanchnic vein,
and this may contribute to long-term patency.
Another factor for stent patency is anticoagulant therapy
to prevent stent-related thrombosis. Many physicians use
anticoagulant therapy [15, 18]. On the other hand, No-
vellas et al. showed that the stent patency rate was 79% in
11 patients without anticoagulation therapy [12]. Kim et
al. indicated the risks of anticoagulant therapy, including
bleeding from the percutaneous transhepatic route, GI
bleeding, and heparin-induced thrombocytopenia [11].
Stent occlusion associated with acute thrombus formation
after stent placement is an important issue, and acute
thrombosis can be prevented by anticoagulant therapy as
soon as possible after stent placement. Therefore, we
treated all of our patients with anticoagulant therapy. No
hemorrhagic complication was found in this study. How-
ever, acute stent occlusion due to thrombus formation was
found in two patients who underwent anticoagulant ther-
apy with heparin on the day of stent placement. Further
prospective studies should be conducted to examine the
efficacy of anticoagulant therapy.
Conclusion
Portal vein stent placement for patients with portal vein
stenosis after hepatobiliary pancreatic surgery is performed
safely and has good long-term patency. Our data strongly
recommend embolization to block blood flow in a collateral
vein during portal vein stent placement, because the pres-
ence of a collateral vein is the only variable related to the
development of stent occlusion.
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